Treatment of pseudobulbar affect in ALS: October 26 highlight and commentary

Neurology. 2005 May 24;64(10):1821; author reply 1821. doi: 10.1212/wnl.64.10.1821.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Amyotrophic Lateral Sclerosis / complications*
  • Antitussive Agents / metabolism
  • Antitussive Agents / therapeutic use
  • Clinical Trials as Topic / standards
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP2D6 / metabolism
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Cytochrome P-450 Enzyme Inhibitors
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism
  • Dextromethorphan / metabolism
  • Dextromethorphan / therapeutic use*
  • Drug Combinations
  • Drug Resistance / genetics
  • Drug Synergism
  • Enzyme Inhibitors / therapeutic use
  • Genetic Testing / standards
  • Genotype
  • Humans
  • Pseudobulbar Palsy / drug therapy*
  • Pseudobulbar Palsy / etiology*
  • Pseudobulbar Palsy / physiopathology
  • Quinidine / therapeutic use*

Substances

  • Antitussive Agents
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Cytochrome P-450 Enzyme Inhibitors
  • Drug Combinations
  • Enzyme Inhibitors
  • Dextromethorphan
  • Cytochrome P-450 Enzyme System
  • Cytochrome P-450 CYP2D6
  • Quinidine